CNS diseases – Page 2

Post authorization safety study comparing quetiapine to risperidone and olanzapine

OBJECTIVES: To compare rates of specific adverse outcomes between patients starting quetiapine, olanzapine, or risperidone use in the Netherlands. METHODS: Observational study using the PHARMO Database Network, including patients starting quetiapin(4658), olanzapine (5856), or risperidone (7229) in 2000-2009, comparing rates of all-cause mortality, failed suicide attempts, extrapyrimidal symptoms (EPS), diabetes mellitus (DM), hypothyroidism, and acute myocardial infarction (AMI)

1 July 2016

Treatment with rivastigmine or galantamine and risk of urinary incontinence: results from a Dutch database study

BACKGROUND: Treatment of Alzheimer disease (AD) with cholinesterase inhibitors (ChEIs) may increase the risk of urinary incontinence (UI). OBJECTIVE: To assess whether ChEI use was associated with the risk of UI among older patients with AD. METHOD: A crossover cohort study using the PHARMO Record Linkage System included 10 years of data on drug dispensing histories for over two million Dutch residents

1 March 2015

Association between ADHD drug use and injuries among children and adolescents

To study the association between attention deficit hyperactivity disorder (ADHD) drug use and the incidence of hospitalization due to injuries. A random sample of 150,000 persons (0-18 years) was obtained from the Dutch PHARMO record linkage systemAn ADHD medication cohort as well as an up to six age/sex/index date sampled control cohort with no history of ADHD drug use was formed

1 February 2014

The effects of Psychotropic drugs On Developing brain (ePOD) study: methods and design

BACKGROUND: Animal studies have shown that methylphenidate (MPH) and fluoxetine (FLX) have different effects on dopaminergic and serotonergic system in the developing brain compared to the developed brain. The effects of Psychotropic drugs On the Dveloping brain (ePOD) study is a combination of different approaches to determine whether there are related findings in humans

1 January 2014

Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen

Tamoxifen is a largely inactive pro-drug, requiring metabolism into its most important metabolite endoxifen. Since the cytochrome P450 (CYP) 2D6 enzyme is primarily involved in this metabolism, genetic polymorphisms of this enzyme, but also drug-inuced CYP2D6 inhibition can result in considerably reduced endoxifen formation and as a consequence may affect the efficacy of tamoxifen treatment

1 June 2013

Use of rivastigmine or galantamine and risk of adverse cardiac events: a database study from the Netherlands

BACKGROUND: Two cholinesterase inhibitors (ChEIs), rivastigmine and galantamine, are used to treat Alzheimer disease in the Netherlands. Several adverse cardiac events have been reported for these medications. OBJECTIVE: We aimed to assess if the ue of ChEIs increased the risk of cardiac events in the Netherlands

1 December 2012

Differences in lithium use patterns in the Netherlands: comparing middle-aged and older patients in a database study

BACKGROUND: Age-dependent changes in lithium pharmacokinetic and pharmacodynamic properties can influence lithium use in an aging population, especially as newer treatment options are available. OBJECTIVE: We compared lithium use patterns between mddle-aged and elderly outpatients in the Netherlands

1 June 2012

Risk of fractures in patients with multiple sclerosis: a population-based cohort study

OBJECTIVE: To examine the risk of fracture in patients with multiple sclerosis (MS) compared with population-based controls. METHODS: A population-based cohort study was performed in the Dutch PHARMO Record Linkage System (1998-2008). Patients withMS (n = 2,415) were matched by year of birth, sex, and practice to up to 6 patients without MS (controls)

1 June 2012

The risk of new onset heart failure associated with dopamine agonist use in Parkinson’s disease

The aim of present study was to investigate the risk of heart failure associated with dopamine agonist use in patients with Parkinson’s disease. The data sources of this study were four different population-based, healthcare databases in United Kindom, Italy and Netherlands. A case control study nested within a cohort of Parkinson’s disease patients who were new users of either dopamine agonist or levodopa was conducted

1 March 2012

Dopamine agonists and ischemic complications in Parkinson’s disease: a nested case-control study

BACKGROUND: It has been suggested that ergoline dopamine agonists can cause ischemic complications. The effect of dopamine agonists in general on the prevalence of ischemic events in patients with Parkinson’s disease (PD) has not been studied. OBJETIVE: Our aim was to investigate the association between the use of dopamine agonists and hospitalization due to ischemic events in patients with PD

1 January 2012

Post authorization safety study comparing quetiapine to risperidone and olanzapine

Treatment with rivastigmine or galantamine and risk of urinary incontinence: results from a Dutch database study

Association between ADHD drug use and injuries among children and adolescents

The effects of Psychotropic drugs On Developing brain (ePOD) study: methods and design

Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen

Use of rivastigmine or galantamine and risk of adverse cardiac events: a database study from the Netherlands

Differences in lithium use patterns in the Netherlands: comparing middle-aged and older patients in a database study

Risk of fractures in patients with multiple sclerosis: a population-based cohort study

The risk of new onset heart failure associated with dopamine agonist use in Parkinson’s disease

Dopamine agonists and ischemic complications in Parkinson’s disease: a nested case-control study

Filter by

Therapeutic area’s

Type of study

More information?